Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Development and external validation of 1- and 2-year mortality prediction models in cystic fibrosis

Sanja Stanojevic, Jenna Sykes, Anne L. Stephenson, Shawn D. Aaron, George A. Whitmore
European Respiratory Journal 2019 54: 1900224; DOI: 10.1183/13993003.00224-2019
Sanja Stanojevic
1Translational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
2Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Sanja.Stanojevic@sickkids.ca
Jenna Sykes
3Keenan Research Centre in the Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne L. Stephenson
2Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
4Adult CF Program, St Michael's Hospital, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shawn D. Aaron
5The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George A. Whitmore
6Desautels Faculty of Management, McGill University, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction We aimed to develop a clinical tool for predicting 1- and 2-year risk of death for patients with cystic fibrosis (CF). The model considers patients' overall health status as well as risk of intermittent shock events in calculating the risk of death.

Methods Canadian CF Registry data from 1982 to 2015 were used to develop a predictive risk model using threshold regression. A 2-year risk of death estimated conditional probability of surviving the second year given survival for the first year. UK CF Registry data from 2007 to 2013 were used to externally validate the model.

Results The combined effect of CF chronic health status and CF intermittent shock risk provided a simple clinical scoring tool for assessing 1-year and 2-year risk of death for an individual CF patient. At a threshold risk of death of ≥20%, the 1-year model had a sensitivity of 74% and specificity of 96%. The area under the receiver operating curve (AUC) for the 2-year mortality model was significantly greater than the AUC for a model that predicted survival based on forced expiratory volume in 1 s <30% predicted (AUC 0.95 versus 0.68 respectively, p<0.001). The Canadian-derived model validated well with the UK data and correctly identified 79% of deaths and 95% of survivors in a single year in the UK.

Conclusions The prediction models provide an accurate risk of death over a 1- and 2-year time horizon. The models performed equally well when validated in an independent UK CF population.

Abstract

This clinical tool considers patients' overall health status and the risk of intermittent shock events to predict 1- and 2-year risk of death for patients with cystic fibrosis. The model accurately predicted death for patients in Canada and the UK. http://bit.ly/2Wbnyaq

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Conflict of interest: S. Stanojevic has nothing to disclose.

  • Conflict of interest: J. Sykes has nothing to disclose.

  • Conflict of interest: A.L. Stephenson has nothing to disclose.

  • Conflict of interest: S.D. Aaron has nothing to disclose.

  • Conflict of interest: G.A. Whitmore has nothing to disclose.

  • Received February 1, 2019.
  • Accepted May 6, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 3 Table of Contents
European Respiratory Journal: 54 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development and external validation of 1- and 2-year mortality prediction models in cystic fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Development and external validation of 1- and 2-year mortality prediction models in cystic fibrosis
Sanja Stanojevic, Jenna Sykes, Anne L. Stephenson, Shawn D. Aaron, George A. Whitmore
European Respiratory Journal Sep 2019, 54 (3) 1900224; DOI: 10.1183/13993003.00224-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Development and external validation of 1- and 2-year mortality prediction models in cystic fibrosis
Sanja Stanojevic, Jenna Sykes, Anne L. Stephenson, Shawn D. Aaron, George A. Whitmore
European Respiratory Journal Sep 2019, 54 (3) 1900224; DOI: 10.1183/13993003.00224-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Self-titration of ICS and β2-agonist in mild asthma
  • Response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthma
  • Risks for cold frequency vary by sex
Show more Original Articles

Cystic fibrosis

  • Morbidity and mortality in carriers of the CFTR Phe508del mutation
  • Structural determinants of long-term and functional outcomes in children with CF
  • Early markers of cystic fibrosis structural lung disease
Show more Cystic fibrosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2020 by the European Respiratory Society